EVIDENCE LIBRARY
Why a youth depression trial protocol chose midazolam as an active control
The SKY-D protocol used midazolam to help mask treatment assignment in a ketamine trial. Its design does not establish an antidepressant effect for midazolam.
The SKY-D protocol used midazolam to help mask treatment assignment in a ketamine trial. Its design does not establish an antidepressant effect for midazolam.
The planned comparison
The protocol described a double-masked randomized trial for people aged 16 to 25 with moderate-to-severe major depressive disorder. It planned four weekly subcutaneous administrations of ketamine or midazolam alongside usual treatment. The primary endpoint was the change in depression rating after four weeks. Later assessments were planned to examine persistence of effects and safety.
What the active control is meant to do
Midazolam was selected because participants can experience noticeable subjective effects after receiving it. If one group receives a perceptible drug and the other receives an inert injection, participants may guess which treatment they received. Using an active control was intended to reduce that risk. The design does not guarantee successful masking: the experiences under the two drugs need not be identical.
How to interpret the protocol
The document describes a planned comparison, not completed results. It cannot establish that either treatment improved symptoms or quantify the adverse events in either group. It also does not compare midazolam against no treatment; both groups received usual care. When reviewing claims drawn from this research, ask whether the document is a protocol or a results paper, what outcome was assessed, and when it was measured. A short-lived subjective drug effect and a sustained change in a depression score are different outcomes.
Source paper
Original analysis of the supplied journal article, identified as PMC10594918.